IS7501A - thurrdufts innöndunar samsetning - Google Patents

thurrdufts innöndunar samsetning

Info

Publication number
IS7501A
IS7501A IS7501A IS7501A IS7501A IS 7501 A IS7501 A IS 7501A IS 7501 A IS7501 A IS 7501A IS 7501 A IS7501 A IS 7501A IS 7501 A IS7501 A IS 7501A
Authority
IS
Iceland
Prior art keywords
dry powder
powder inhalation
inhalation composition
composition
dry
Prior art date
Application number
IS7501A
Other languages
English (en)
Inventor
Charles Roche Trevor
Arvind Bulsara Pallav
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of IS7501A publication Critical patent/IS7501A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS7501A 2002-04-13 2004-10-11 thurrdufts innöndunar samsetning IS7501A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0208609.8A GB0208609D0 (en) 2002-04-13 2002-04-13 Compositions
PCT/GB2003/001595 WO2003088944A1 (en) 2002-04-13 2003-04-10 Dry powder inhalant composition

Publications (1)

Publication Number Publication Date
IS7501A true IS7501A (is) 2004-10-11

Family

ID=9934856

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7501A IS7501A (is) 2002-04-13 2004-10-11 thurrdufts innöndunar samsetning

Country Status (19)

Country Link
US (2) US20050232998A1 (is)
EP (1) EP1509199A1 (is)
JP (1) JP2005529874A (is)
KR (1) KR20040097348A (is)
CN (1) CN100362986C (is)
AR (1) AR039408A1 (is)
AU (1) AU2003224278A1 (is)
BR (1) BR0309115A (is)
CA (1) CA2482249A1 (is)
GB (1) GB0208609D0 (is)
IL (1) IL164421A0 (is)
IS (1) IS7501A (is)
MX (1) MXPA04010082A (is)
NO (1) NO20044496L (is)
PL (1) PL373293A1 (is)
RU (1) RU2004130438A (is)
TW (1) TW200407174A (is)
WO (1) WO2003088944A1 (is)
ZA (1) ZA200408247B (is)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487417A4 (en) 2001-09-17 2010-03-17 Glaxo Group Ltd DRY POWDER DRUG FORMULATIONS
EP1643974A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Inhalable pharmaceutical formulations comprising a sugar ester
BRPI0606364A2 (pt) 2005-02-10 2010-03-23 Glaxo Group Ltd processo para formar lactose adequada para uso em uma formulaÇço farmacÊutica
GB0605723D0 (en) * 2006-03-23 2006-05-03 3M Innovative Properties Co Powder filling processes
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
ES2452965T3 (es) * 2007-09-05 2014-04-03 Rigel Pharmaceuticals, Inc. Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
TR201007251A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Kalsiyum kanal blokörü formülasyonu.
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
CN107875127A (zh) * 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
PL3517541T3 (pl) 2012-05-08 2020-12-28 Nicox Ophthalmics, Inc. Postać polimorficzna propionianu flutykazonu
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
WO2014014650A1 (en) 2012-07-19 2014-01-23 3M Innovative Properties Company Powder feeding apparatus
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
MX2015015132A (es) * 2013-04-29 2016-02-18 Sanofi Sa Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
CN104644618A (zh) * 2013-11-19 2015-05-27 上海医药工业研究院 一种干粉吸入剂及其制备方法
CA2991760C (en) * 2014-07-31 2025-05-06 Aspeya US Inc. DRY INHALATION POWDER FORMULATIONS
WO2016052897A1 (en) * 2014-09-30 2016-04-07 Hanmi Pharm. Co., Ltd. Dry powder for inhalation formulation having improved stability of combined active ingredients
KR20160117069A (ko) * 2015-03-31 2016-10-10 한미약품 주식회사 복합 활성성분의 안정성이 개선된 흡입용 캡슐제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) * 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
AU591152B2 (en) * 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
IL95590A (en) * 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
WO1999001463A2 (en) * 1997-07-03 1999-01-14 Quadrant Holdings Cambridge Limited Modified glycosides, compositions comprised thereof and methods of use thereof
US6352722B1 (en) * 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
EP1343521A2 (en) * 2000-12-01 2003-09-17 Battelle Memorial Institute Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations
CN100496608C (zh) * 2001-03-30 2009-06-10 洁垢技术有限公司 药用气溶胶制剂
EP1507754A1 (en) * 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists

Also Published As

Publication number Publication date
CN100362986C (zh) 2008-01-23
TW200407174A (en) 2004-05-16
BR0309115A (pt) 2005-02-01
ZA200408247B (en) 2006-03-29
US20080060645A1 (en) 2008-03-13
AR039408A1 (es) 2005-02-16
GB0208609D0 (en) 2002-05-22
WO2003088944A1 (en) 2003-10-30
JP2005529874A (ja) 2005-10-06
PL373293A1 (en) 2005-08-22
IL164421A0 (en) 2005-12-18
RU2004130438A (ru) 2005-06-10
US20050232998A1 (en) 2005-10-20
AU2003224278A1 (en) 2003-11-03
NO20044496L (no) 2004-11-15
CN1658837A (zh) 2005-08-24
KR20040097348A (ko) 2004-11-17
MXPA04010082A (es) 2004-12-13
CA2482249A1 (en) 2003-10-30
EP1509199A1 (en) 2005-03-02

Similar Documents

Publication Publication Date Title
ATE543529T1 (de) Trockenpulverinhalator
DK3354263T3 (da) Tørpulverformuleringer
ATE503517T2 (de) Pulverinhalator
EP1487524A4 (en) INHALER FOR DRY POWDER
ATE460955T1 (de) Trockenpulver-inhalator
NO20022414D0 (no) Tiotropium-inneholdende inhalasjonspulver
DE60310914D1 (de) Pulverzusammensetzung
DE60221611D1 (de) Trockenpulverinhalator
NO20035442L (no) Pulverlakksammensetning
IL174735A (en) Dry powder inhaler
IL164421A0 (en) Dry powder inhalant composition
DK1539089T3 (da) Reducerede aerosol-genererende formuleringer
IS7500A (is) thurrdufts samsetningar
GB0321610D0 (en) Dry powder inhaler
NO20043489L (no) Sammensetning for inhalering
DK1567135T3 (da) Tiotropiumholdig pulverformulering til inhalation
GB0319667D0 (en) Dry powder inhaler
DE10313033A8 (de) Pulverlackzusammensetzung